Yazar "Kirhan, Idris" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Evaluation of sleep quality and daytime sleepiness in nurses
    (2019) Uzer, Fatih; Kirhan, Idris
    Aim: In this study, it was aimed to experimentally investigate the protective effects of melatonin in the cisplatin-induced ototoxicity.Material and Methods: Ten Wistar-albino rats were included in the study. Two equal groups were generated randomly as cisplatin and melatonin groups. Rats’ underwent Auditory Brainstem Response (ABR) and Distortion Product Otoacoustic Emission (DPOAE) testing before the drug administration and the results were recorded. Both tests were repeated 72 hours after the cisplatin administration in all rats.Results: Significant difference was found between the I-IV interval values before the treatment and after the treatment both in cisplatin and melatonin group. As well as the significant difference in hearing threshold value changes, statistically, significant differences in ABR-I and ABR-IV interval variations were also seen between the cisplatin and melatonin groups. A statistically significant decrease was found between the initial and final control SNR (signal-to-noise ratio) levels within the cisplatin group in the evaluations at 2000Hz, 3000Hz and 4000Hz. Statistically, significant differences were observed between SNR levels when the melatonin group was compared with the cisplatin group. Conclusion: Melatonin appears to reduce cisplatin-induced ototoxicity in rats. Although, the use of supplementary therapies targeting to reduce the toxic effects in clinical studies is still a controversial point.
  • Küçük Resim
    Öğe
    Examination of pulmonary embolism in patients in a university hospital
    (2020) Kirhan, Idris; Uzer, Fatih; Hocanli, Iclal; Turan, Hamdiye
    Aim: Pulmonary embolism (PE) is responsible for 5-15% of hospital deaths. The rate of mortality from PE in untreated cases is about 25-30%, while this rate drops down to 2-8% in treated cases. In this study, we aimed to investigate general features of the patients hospitalized in our center due to PE and the factors affecting prognosis. Material and Methods: Patients hospitalized due to PE in Harran University Medical Faculty Hospital between January 2015 and December 2017. Patients’ demographic data, comorbidities, hemogram outcomes at the time of admission, liver function tests, renal function tests, electrolytes and cardiac markers, status of the patients during follow-up (referral to intensive care unit, exitus, ward follow-up) and PE clinical picture (massive, submassive, nonmassive) were recorded. All patients requiring hospitalization due to PE were included in the study, while patients with chronic thromboembolic pulmonary disease, those requiring recurrent hospitalization and patients discharged on own demand were excluded from the study.Results: The study included 40 (38.8%) male and 63 (61.2%) female patients with a mean age of 66±18.1 years. The mean duration of hospitalization was found as 11 days. Of the patients included in this study, 7.7% (n=8) were diagnosed with massive, 10.6% (n=11) with submassive, and 81.5% (n=84) with non-massive PE. Four patients (3.8%) were accepted as in-hospital exitus, 30 (29.1%) patients were transferred to the intensive care unit and 69 (66.9%) patients were followed-up in the thoracic diseases service. When patients diagnosed with non-massive PE were compared with those diagnosed with submassive and massive PE; the levels of magnesium (p=0.003), and troponin (p=0.000) were statistically significantly higher in the group diagnosed with submassive and massive PE. When the groups with and without the need for intensive care were compared, platelet counts were statistically lower in the group which required intensive care (p=0.038).Conclusion: More often hospitalization is needed in female patients due to PE. Although routine laboratory tests give a partial information about the prognosis of PE, cardiac markers are the most commonly used in clinical practice.
  • Küçük Resim
    Öğe
    Serum prolidase, urotensin-2 and nesfatin levels in patients with compensated or uncompensated cirrhosis
    (2019) Aydin, Ferzan; Cindoglu, Cigdem; Kirhan, Idris; Uyanikoglu, Ahmet; Yenice, Necati
    Aim: To assess the feasibility of serum prolidase, urotensin-2, and nesfatin measurements as diagnostic and follow-up markers of compensated or uncompensated cirrhosis. Material and Methods: The study included 97 cirrhosis patients and 51 healthy individuals who were admitted to the Internal Medicine and Gastroenterology Clinics of Harran University Research and Application Hospital between May 2014 and June 2015. Patients with esophageal variceal bleeding, ascites, hepatic encephalopathy were considered as having decompensated cirrhosis. Blood samples obtained from patient and control groups were stored at -85 C. ELISA methodology was used for measurements.Results: A total of 97 cirrhotic patients (43 with compensated and 54 with decompensated cirrhosis) with a median age of 53.98±15.67 years (range: 19-89) were included in the study. Serum prolidase, urotensin-2, and nesfatin in patients with cirrhosis compared to 51 healthy controls. Serum prolidase levels were significantly lower in the overall group of patients with cirrhosis as well as in the decompensated cirrhotic patients as compared to controls (p0.001). Urotensin-2 was significantly lower in the compensated cirrhosis group than in controls (p0.05). Nesfatin was significantly higher in the overall and decompensated cirrhotic than in controls (p0.05).Conclusion: Our results suggest that serum prolidase levels can be used as a marker for diagnosis and follow-up in patients with decompensated cirrhosis and that urotensin-2 may play a role in the pathogenesis of cirrhosis. Again, a higher nesfatin level in the overall and decompensated cirrhosis patients was suggestive of its potential role in the development of loss of appetite and cachexia characteristic of advanced cirrhosis as well as a role as a potential marker.Keywords: Cirrhosis; prolidase; urotensin-2; nesfatin.